Background: Cytogenetic and molecular genetic markers have been used recently to stratify risk and predict prognosis of different types of cancers. Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that plays an important role in the pathogenesis of many diseases, such as autoimmune diseases and cancers. We studied MIF gene expression behavior to investigate its prognostic impact in childish patients with acute lymphoblastic leukemia (ALL). Multivariate cox-regression analysis adjustment confirmed that high MIF expression was the only independent prognostic factor in ALL patients for OS and DFS in our study (p = 0.004, p = 0.01 respectively). Conclusions: We found that MIF expression is an important prognostic factor in ALL patients with normal karyotype, and its incorporation into novel risk-adapted therapeutic strategies will improve the current cure rates for this group of patients. (Clin. Lab. 2018;64:xx-xx.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is a disease characterized by the production of a large number of Immature lymphocytes (lymphoblasts) by the bone marrow [1] . Cure rates have been increased recently with the disease-free survival exceeding 75% of the cases. Trials continue to find better treatment strategies to enhance these rates [2] . Genetic alterations are important param-eters in the disease development and have been used to stratify the risk by the world health organization [3] . ALL is mainly characterized by the presence of one or more acquired genetic alteration [4, 5] . Cytogenetic and molecular genetic findings constitute important, independent prognostic factors in both childhood and adult ALL [6] [7] [8] [9] [10] [11] [12] [13] [14] . Normally cytogenetic ALL accounts for 30 -40% of pediatric patients [7, 15, 16] and those patients are considered at intermediate risk or relatively favorable at the best case [15, 16] . The expression behavior of the leukemic blasts can be used to predict the disease prognosis in absence of cytogenetic alterations [17, 18] . The human macrophage migration inhibitory factor (MIF) gene on chromosome 22 (22q11.2) [19, 20] was first identified in 1966 as a molecule that inhibits the migration of macrophages [21, 22] . The gene encodes a protein which has a role in cell-mediated immunity and is considered as a cytokine that mediates inflammation through binding to CD74 immune cells [23] [24] [25] . In addition, MIF was found to have a role in angiogenesis and tumor cell proliferation, thus rendering it an interesting target for study [26] . Elevated MIF expression has been found in hepatocellular carcinoma [27] , breast cancer [28] , prostate cancer [29] , colon cancer [30] , head and neck cancer, and adenocarcinomas of the lung [31] and was found to be related with disease aggressiveness. We studied MIF gene expression patterns within acute lymphoblastic leukemia of children to evaluate its prognostic impact on the disease and to help in creating better treatment strategies.
MATERIALS AND METHODS

Patients
Sixty patients with ALL were diagnosed, treated only with chemotherapy (ALL-BFM 90 protocol), and had been followed up until death or for periods up to 36 months (between 2014 and 2017) in the oncology center Mansoura University (OCMU) Hospital. The patients were 37 males and 23 females; their ages ranged from 2 to 18 years (mean 9.62 ± 5.1). In addition, 50 healthy volunteers with matched age (5 -18, mean 9.76 ± 3.99) and gender (31 females, 19 males) were included in the study, after prior consent. Cases were selected for the analysis according to sample availability (bone marrow, peripheral blood and the presence of cytogenetic and clinical data). The cases were diagnosed by bone marrow aspiration, immunophenotyping, and cytogenetic analysis. Immunophenotyping characterization divided the patients into 43 B-cell cases (71.6%) and 17 T-cell ALL cases (28.3%). Cytogenetic analyses of bone marrow (BM) or peripheral blood (PB) were performed. Metaphase chromosomes were banded by G-banding technique and karyotyped according to the International System for Human Cytogenetic Nomenclature. A minimum of 20 metaphases had to be examined for a patient to be classified as having normal cytogenetics. Cases with cytogenetic aberrations were excluded, hence, all B-cell cases were in B-cell lymphoblastic leukemia not otherwise specified category according to WHO classification. The follow-up time started from the diagnosis date until the date of the last contact with the patients known to be alive.
MIF mRNA expression by quantitative real-time PCR Total RNA was isolated from peripheral blood using the QIAamp RNA Blood Mini kit (QIAGEN, Hilden, Germany). cDNA is reverse transcribed from 1 µg of the total RNA extracted using random hexamers and MultiScribe Reverse Transcriptase enzyme (High Capacity cDNA Kit; Applied Biosystems, Foster City, CA, USA). Quantitative real-time PCR is then performed as follows: each sample was analyzed in duplicate; glucose 6-phosphate dehydrogenase (G6PDH) and MIF were coamplified in the same tube. The tube contains G6PDH probe (FAM-5CAAGCTTCCGTTCTCA-GCC-3-TMRA) with G6PDH forward (5ʹ-CTGCCAT CA-TGCCGAT-GTTCA-3ʹ) and reverse (5ʹ-GAAG-ATGGTGATGGGATTTC-3ʹ) primers, and MIF probe (FAM-5ʹ TCCT-TCTGCCATCATGCCGATGTT-3ʹ-TMRA) with MIF forward (5ʹ CTGCCATCATGCC GA-TGTTCA-3ʹ) and reverse (5ʹ-GTCCCCTCCCGGC AAACC-3ʹ) primers. The reaction mixture was performed in a final volume of 50 µL containing 20 µL cDNA, 400 µM of each primer and 25 µL Taq PCR master mix (2.5 units Taq DNA polymerase, 1x PCR buffer, and 200 µM of each dNTP) (Taq PCR master kit, Qiagen, Hilden, Germany). Reactions were performed using real-time PCR 7000 sequence detection system (Applied Biosystems, Foster City, USA). Amplification was carried out at 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 PCR cycles at 95°C for 15 seconds, and 60°C for 1 minute. MIF mRNA expression was normalized to the simultaneously analyzed glucose-6-phosphate dehydrogenase (G6PDH). The comparative cycle threshold (CT) method was used to determine the relative MIF expression levels, and the cycle number difference (Δ CT = CT G6PDH -CT MIF) was calculated for normal and ALL cases. ∆CT of ALL samples was normalized to the ∆CT of normal samples (Δ∆CT = ∆CT ALL -∆CT Normal ). Relative MIF expression values are calculated from the equation 2 -ΔΔCT ( Figure 1 ).
Statistical analysis
To evaluate the impact of MIF expression values on ALL prognosis, ALL samples were divided by the median expression value into two expression groups: low MIF expressers if they had expression values within the lower 50% and high MIF expressers if they had MIF expression values within the upper 50%. Clinical features across groups were compared using the χ 2 or a two-sided Fisher's exact test for categorical variables and the nonparametric Mann-Whitney U test for continuous variables. A p-value less than 0.05 was considered significant. The Kaplan-Meier estimator was used to an-alyze DFS and OS and the log-rank test was used to compare differences between survival curves. Logistic regression was carried out using odds ratio. To determine whether MIF was the only parameter associated with outcome or not, we performed multivariate Cox-regression analysis with proportional hazards for MIF and other prognostic variables on overall and disease-free survival. All data analyses were done using SPSS software, version 22.
Clinical end point
Complete remission required an absolute neutrophil count of at least 1,500/μL, a platelet count of at least 100 x 10 9 /L, no peripheral blood blasts, bone marrow cellularity more than 20% with maturation of all cell lines, less than 5% bone marrow blasts, and no extramedullary leukemia. Relapse was defined as the reappearance of circulating blasts, or greater than 5% blasts in the marrow not attributable to another cause, or development of extramedullary leukemia. Primary resistance to chemotherapy or refractory was defined as more than 25% blasts in the BM, lack of regeneration of normal hematopoiesis, persistence of PB blasts, or extramedullary leukemia after induction. Disease-free survival (DFS) was defined only for those patients achieving a CR. It was measured from the CR date until date of relapse or death, regardless of cause, censoring for patients alive at last follow-up. Overall survival (OS) was measured from the protocol on study date until the date of death regardless of cause, censoring for patients alive at last follow-up.
RESULTS
MIF expression and Clinical Features
In our study among 60 ALL patients, there were 31 (51.7%) patients with high MIF expression in comparison to 29 (48.3%) patients with low expression. No statistical differences were observed between patients with low and high MIF expression with respect to age (p = 0.13), gender (p = 0.55), WBC count (p = 0.06), Hb concentration (p = 0.62), platelet count (p = 0.97), percentage of BM blasts (p = 0.8), and PB blast (p = 0.07) or other presenting physical and clinical laboratory findings. As regards immunophenotypic characterization, there was no prevalence in one of ALL phenotypes (B-cell and T-cell ALL) among different expression classes (p = 0.07) ( Table 1) .
MIF expression and prognostic impact
The course of the disease in patients with high MIF expression was unfavorable. Patients with high MIF expression were associated with significant low CR rates achieved after induction therapy (25.8% vs. 72.4%, high vs. low MIF, p = 0.001) and high mortality rate (54.8% vs. 20.7, p = 0.007) compare to low MIF expression patients. Again, ALL patients with high MIF expression had a significantly higher tendency to go refractory (51.6% vs. 24.1, p = 0.029) and insignificant relapse risk (19.4% vs. 10.3%, p = 0.32) compared to low MIF expression patients (Table 2) . Kaplan-Meier analysis demonstrated that high MIF expressers had significantly shorter DFS (Figure 2) Table  3) . Applying odds ratio of higher to lower MIF expression showed that patients with high MIF expression were 4.65 times (95% CI: 1.48 -14.6, p = 0.007) more likely to die, 0.13 times (95% CI: 0.042 -0.4, p = 0.001) less likely to achieve complete remission, and 3.81 times (95% CI: 1.26 -11.59, p = 0.01) more likely to have refractory disease than lower MIF expression. Meanwhile, high MIF expressers were 2.08 times (95% CI: 0.46 -9.23, p = 0.32) more likely to be relapsed than low expressers (Table 4) . A multivariate Cox-regression analysis was conducted to determine whether MIF expression represents an independent prognostic marker in normal karyotype ALL or whether other parameters, in the study, were involved. After adjusting the test for the suspected covariates including MIF expression, age, WBCs count, Hb concentration and immunophenotyping, high MIF expression remained the only significant parameter that predicts prognosis based on OS and DFS (p = 0.004 and p = 0.007 respectively) and has the highest hazard ratio for death (HR = 4.9) and relapse (HR = 3.58) for all suspected parameters (Table 5) .
DISCUSSION
Cytogenetic aberrations have recently been used as important prognostic markers for acute lymphoblastic leukemia patients [6] [7] [8] [9] [10] [11] [12] [13] [14] . Cases without such aberrations are considered cytogenetically normal and constitute 30 -40% of ALL cases [7, 15, 16] . The expression behavior of the leukemic blasts can be used to predict the disease prognosis in absence of cytogenetic alterations [17, 18] . Macrophage inhibitory factor (MIF) gene is located on chromosome 22q11.2 and encodes a protein that has a role in cell-mediated immunity and is considered as a cytokine that mediates inflammation through binding to CD74 immune cells [23, 24] . Several studies confirmed the role of MIF in the pathogenesis of many diseases, such as autoimmune diseases [32] [33] [34] [35] and cancers [36] [37] [38] . We studied macrophage migration inhibitory factor (MIF) gene expression pattern in childhood ALL patients since elevated MIF expression had been found in hepatocellular [27] , breast [28] , prostate [29] , colorectal cancer [30] , and adenocarcinomas of the lung [31] . By dividing ALL patients into two groups according to median MIF gene expression, i.e., high and low expression groups, and comparing both groups as regards age and gender, we did not find any significant difference. Previous studies confirmed that the association between MIF expression and age or gender was absent in pa- tients with esophageal squamous cell carcinoma [39] and breast cancer [38] . However, Hardman MJ et al. and Ashcroft GS et al. found increased MIF expression with age and its downregulation by estrogen [40, 41] . In lung adenocarcinoma, Akira Kamimura et al. had found that MIF protein concentration in nuclei has no correlation with gender but its expression was strongly associated with lower age while its cytoplasmic concentration was age-independent [42] . After studying the clinical picture and hematological picture within both expression groups of ALL patients, we found a prevalence of high WBC count in the high MIF expression group but the result was slightly nonsignificant (p = 0.06), which may link the prognostic impact of MIF gene to the elevated WBC count so multivariate analysis of MIF expression with different prognostic parameters was strongly needed to remove confliction. Similarly, for ALL phenotypes there was a slightly nonsignificant prevalence of B-cell ALL within high MIF expression group (p = 0.07). However, the increased MIF expression within the B-Cell ALL phenotype may come from the prevalence of B-cell ALL in the disease [43] or the expression of CD74 on the B-cell surface that was thought to function mainly as an MHC class II chaperone which regulates B-cell differentiation and is considered as an MIF protein receptor b [44] . By studying the prognostic impact of MIF expression on the outcome of ALL patients we found that the elevated expression is closely associated with unfavorable prognosis. High MIF expression was significantly linked to higher refractory and mortality rates (p = 0.029, p = 0.007, respectively) and lower complete remission rate (p = 0.001). It was also linked to higher relapse rates (p = 0.32) but the result was nonsignificant. In addition, high MIF expressers were 4.65 times more likely to die, 3.81 times more likely to give no response to induction therapy, and 0.13 times to go into complete remission while they are 2.08 times more likely to relapse in comparison to low MIF expressers. Also, from survival analysis data, we find that higher MIF expressers significantly tend to have shorter overall and disease-free survival with lower cumulative survival (p = 0.001). All previously discussed data illustrate the bad prognostic impact of MIF high expression in ALL cases.
Since parameters like WBC count, age, ALL phenotype, and hemoglobin concentration are considered to have a prognostic impact for ALL patients, we did a multivariate Cox-regression analysis for these factors with MIF expression. After adjusting the experiment, we found that high MIF expression was the only significant parameter based on overall and disease-free survival (p = 0.004, p = 0.007) in our study; hence, it is considered an independent prognostic factor in pediatric patients with ALL which elevated expression linked with bad prognosis. The prognostic impact of MIF expression has not yet been studied in ALL but it has been studied in other cancer types and considered as an indicator of cancer aggressiveness. In esophageal squamous cell carcinoma MIF high expression is linked with shorter survival and microvessel density through induction of VEGF and IL-8 secretion in serum [39] . High expression also found in non-small cell lung cancer is associated with risk of recurrence after resection [45] and in colonic adenocarcinoma than compared to normal cells but without clinical significance in outcome [30] . High expression in breast cancer cells was associated with microvessel density and poor disease-free survival (p = 0.029) and overall survival but the result was not significant (p = 0.17) [38] . Several mechanisms have been discussed by which MIF overexpression enhances malignancies. MIF sustains macrophage viability since it was shown that macrophages lacking MIF are more likely to go to apoptosis [46] . Consequently, the tumor-associated macrophages (TAMs) are able to support the malignant potential of tumor cells [47] . Autocrine MIF activation of Th2 [48] and suppression of Th1 [49] suppress the immune system and enable further tumor growth and progression [48] . Androgen-independent prostate cancer required MIF-activated signal transduction pathways for both growth and invasion [50] . MIF knockdown in androgen-independent prostate cancer [50] and in lung adenocarcinoma [31] decreases cell proliferation and invasiveness, in contrast, an adverse effect was achieved when MIF was overexpressed. MIF induces angiogenesis by inducing differentiation of endothelial cells [51, 52] . In glioblastoma, anti-MIF antibodies inhibit angiogenesis [53] MIF also was found to inhibit P53 tumor suppressor activity [54] . All those studies suggest the correlation of MIF with cancer development and prognosis.
CONCLUSION
In summary, we concluded that elevated MIF expression successfully identifies high-risk patients within the cytogenetically normal pediatric ALL cases. It is associated with higher mortality rates, lower complete remission rates, lower OS and DFS. Adjustment of treatment adapted strategies for this ALL group would be effective to achieve a better outcome.
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